An article previewing an AI-designed preclinical drug candidate for ocular and inflammation-related indications, highlighting its development and therapeutic potential.
Key Takeaways
- Insilico nominated ISM9077 as a preclinical candidate targeting a moderately novel Target Y molecule
- Preclinical data show retinal exposure 2–5.5 times plasma and efficacy after oral and topical delivery
- ISM9077 reduced ocular inflammation and outperformed cyclosporine A in dry eye and uveitis models